I've been looking into INOVIO Pharmaceuticals (INO), and I think this could be an interesting short-squeeze candidate heading into the end of October.

Not saying a squeeze is guaranteed, but there are some interesting ingredients here.

Short Interest

According to September 30 short-interest data: 20.82 million shares short

Approximately 20–25% of the float shorted (depending on the float estimate)

7.59 days to cover based on average trading volume

Short interest increased from approximately 19.9 million shares in mid-September.

That's a substantial bearish position heading into a potentially major catalyst

The Catalyst — October 30, 2026

INOVIO has an FDA decision target of October 30 for INO-3107, its treatment for recurrent respiratory papillomatosis (RRP), a rare disease that causes recurring growths in the respiratory tract.

A favorable decision could significantly change the company's outlook and potentially attract new investors.

However, approval isn't guaranteed. The FDA previously raised concerns about whether the treatment qualifies for accelerated approval. That said, it would make a company in cash run-off suddenly available to generate revenue and significantly change their evaluation. They've already began lining up potentially buyers hoping for a good decision.

Why I Think a Short Squeeze Is Possible

Here's the potential setup:

FDA announces positive news.

Investors begin buying INO, pushing the stock higher.

Short sellers start taking losses and some buy shares to close their positions.

That covering creates additional buying pressure.

If momentum and trading volume accelerate, the rally could feed on itself.

With roughly a quarter of the float reportedly shorted, an unexpected positive catalyst could make things interesting.

Another Potential Catalyst

INO also has an estimated earnings report around November 10, shortly after the FDA decision.

If approval happens, investors could be looking for updates on commercialization, launch timing, and future revenue potential.

I'm not expecting meaningful drug sales to materialize immediately, but management commentary could influence sentiment.

The Risks

This is a speculative biotech play, not a guaranteed squeeze.

The FDA could reject or delay approval.

High short interest doesn't guarantee forced covering.

Financing needs and potential dilution could limit upside.

The stock could fall sharply on unfavorable news.

My Take

What caught my attention is the timing.

20.8 million shares short, a major FDA decision approaching, and a potential company update shortly afterward.

If the FDA decision is unexpectedly favorable, I think the combination could create conditions for a sharp rally.

I'm personally holding INO calls expiring November 20, so I have a bullish position and could be wrong.

What do you guys think? Is $INO a legitimate short-squeeze candidate, or are the shorts correctly pricing in the FDA risk?

Not financial advice. Do your own DD.

Approval of KETAFREE will be transformative for this pre-revenue company!

For those following NRXP's progress, below is a link to the prior informational post from two weeks ago (which contains a link to prior posts).

NRx Pharmaceuticals (NRXP) - Outstanding DARPA-funding PR published this morning PLUS status update to September Catalysts post from a month ago. The positive catalysts are mounting!

Yesterday's announcement and key points:

NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine | Thu, 10/15/2026 - 08:28

• “The supply of ketamine in the United States has been primarily from overseas manufacture and American hospitals and doctors have been plagued by repeated shortages of this critically important drug.
• We look forward to demonstrating that manufacture of drugs such as this can successfully be re-shored to the United States.

NRXP has the wind at its back now, as they will:

• Have the only preservative(toxin)-free ketamine manufactured in the U.S.
• Be able to fill the gap left wide open by shortages.
• Per the Chief Commercial Officer, have 4M to 5M vials ready to ship immediately upon FDA approval (serious REVENUE incoming)!
• Per the Chief Commercial Officer, enter into a $3B ketamine/esketamine market projected for 2027, which includes not only anesthesia and analgesics (KETAFREE) -- but also psychiatric (NRX-100 NDA about to be filed by NRx).
• Be able to manufacture 1M vials per month.
• Take market share due to all the above.

This company's potential has nothing to do with the current precarious state AI stocks are in, or the market in general. They can all go down but NRXP is in position to rise significantly. It's in a niche market with a very meaningful advantage.

NRXP SHARE PRICE FACTS ... VERY HIGH SHORT INTEREST ... A BEAUTIFUL SETUP:

The NRXP share price has drifted down from $3.50 to $2.70 in the last month. Long-term shareholders and followers of NRXP aren't selling, as they have been waiting months and years for this day.

HERE's WHY THE PRICE HAS COME DOWN:

NRXP — Short‑Interest Snapshot (Sept 30, 2026)

Outstanding Shares: 43,300,000
Public Float: 38,300,000
Shares Sold Short: 9,793,940
Short % of Float: 24.17%
Short % of Shares Outstanding: 22.6%
Days to Cover: 14.0
Dollar Volume Sold Short: $28,600,000
Prior Short Interest: 9,773,562
Change vs Prior Report: +0.21%
Price on Report Date: $2.92
Borrow Fee (Oct 15): 6.3%

• MarketBeat reports short interest as a percentage of float (24.17%).
• CurvedTrading reports short interest as a percentage of outstanding shares (22.6%).
• Both agree on the absolute short interest (≈9.8M) and days to cover (14.0).
• Outstanding shares (43.3M) and float (38.3M) are consistent across sources.

Everyone knows why short sellers might do the above, just prior to highly derisked setup.

Investors and Traders, start your engines ... Let's go!

This is an oldy but goody!!! Has squeezed a few times in the past and looks like they getting ready for another round of squeezing. Annual disclosure has squeeze mentioned in it. Also the use of AI and digital assets for a possible transition. All I rely on is the insiders own 89% of outstanding shares, so get on for 20 or 50 points and get off when you’re happy!!!

🚨 The Squeeze Setup: The Numbers:

Short Percent of Float: ~29.5% – 31.5% (~140.8M+ shares shorted out of ~479M outstanding)

Short Interest Ratio (Days to Cover): 10.3 Days (Extremely high—shorts would need over 2 weeks of normal volume to cover!) 

Off-Exchange Short Volume Ratio: ~57% (Heavy dark pool shorting suppressing true buy pressure) 

Current Stock Price: ~$2.30 – $2.40 (52-Week Range: ~$1.20–$9.39)

Fundamentals & Catalyst Drivers:

1. Massive Contract Backlog: BBAI holds a $270M+ backlog in AI-driven analytics, logistics modeling, and defense contract.

2. Q3 Earnings Date Confirmed: BigBear.ai just officially confirmed it will release its Q3 2026 Financial Results on Tuesday, October 27, 2026. Earnings events are classic triggers for short squeezes when high short interest is present. 

3. Reaffirmed Full-Year Guidance: BBAI reaffirmed FY guidance of $135M–$165M in revenue, backed by a solid cash runway (~$410M cash balance). 

Why the Squeeze Setup is Dangerous for Shorts:

Extremely Vulnerable Shorts: With 10.3 Days to Cover and over 140 Million shares shorted, any sudden buying surge or positive press will lock shorts into an aggressive cover loop.

High-Beta Volatility: $BBAI carries a high beta (~3.1) and has a history of violent 50%–100%+ multi-day runs when retail volume ramps up. 

Action Plan / Key Levels to Watch:

Support Level: $3.20 – $3.50 (Strong historical buying floor)
Breakout Trigger: A clean push past $4.50–$5.00 on heavy volume could trigger an automated cascade of short-covering up toward $7–$9+.

Disclaimer: Not financial advice. Extremely volatile high-beta stock. Always manage your risk with proper stop-losses and position sizing.

Good morning, SqueezeFinders!

The $QQQ tech index tumbled 0.7% to close yesterday at 746.04, which still leaves a small buffer before approaching any level of confidence for bears to begin betting on a newly-forming downtrend below 730-727. The main directional sentiment determinants today are a mix of the below-detailed economic data releases, further developments with the ongoing wars in both the Middle-East/Eastern Europe, and also earnings reports from $UNH, $JPM, $WFC, $JNJ, and $CITI. This market is very dynamic and has been unpredictable as far as risk-tolerance goes, as one day we're running, and the next we're crashing. Stay tuned for what's squeezy. Regardless of broader market sentiment, you can always locate relative strength by checking SqueezeRadar to track irregularities in the data, and find winners you may not have spotted before without our scanners. Also, make sure to check out our newest tool (developed by me), "Dracula's Library"! This tool allows you to quickly gather information on recent catalysts, and analyst/Institutional price targets all in one small graphical interface on our platform, all powered by AI.

🥇 Gold: ~$4,200/oz (+0.2%)
🥈 Silver: ~$60/oz (-0.1%)
🪙 Bitcoin: ~$82.9k/coin (-1.1%)
🛢️ Oil: ~$92.50/barrel (-1.4%)

Today's economic data releases are:

🇺🇸 Fed Waller Speaks @ 3:45AM ET
🇺🇸 OPEC Monthly Report @ 6:00AM ET
🇺🇸 ADP Employment Change Weekly @ 8:15AM ET
🇺🇸 Existing Home Sales (Sep) @ 10:00AM ET
🇺🇸 Federal Budget Balance (Sep) @ 2:00PM ET

📙Breakdown point: BELOW this price, the move will lose momentum significantly in the short-term, as shorts will gain confidence encouraging them to short more. Reducing probability of a squeeze without a catalyst.

📙Breakout point: ABOVE this price, the move will gain momentum significantly in the short-term, as shorts losses will increase pressuring them to cover. Increasing the probability of a squeeze occurring, especially if with a catalyst.

1. $ASC
   Squeezability Score: 41%
   Juice Target: 23.5
   Confidence: 🍊 🍊
   Price: 19.82 (+2.8%)
   Breakdown point: 18.4
   Breakout point: 20.2
   Mentions (30D): 1
   Event/Condition: Shares reached a new 52-week high above $20 as product tanker rates and fleet utilization supported sentiment following the exercise of newbuilding options for additional Handysize vessels + quarterly results earlier in the year topped estimates on revenue with a raised dividend and strong current and quick ratios underscoring balance-sheet strength + analyst upgrades including to Strong Buy reflected confidence in earnings power from the expanded fleet amid firm market conditions + Recent price target 🎯 of $24 from analysts + Recent price target 🎯 of $21 from fair value update + Recent price target 🎯 of $17 from consensus

2. $BMBL
   Squeezability Score: 40%
   Juice Target: 5.7
   Confidence: 🍊 🍊 🍊
   Price: 3.80 (+49.61%)
   Breakdown point: 3.5
   Breakout point: 4.6
   Mentions (30D): 0 🆕
   Event/Condition: Shares surged nearly 50 percent after reports that the company is in advanced talks to be taken private by Ithaca Holdings at roughly a $1 billion valuation implying a substantial premium to the prior market cap + Citi noted that a $1 billion enterprise value would equate to about $6.10 per share while the stock traded well below that level even after the jump + the potential transaction comes as the dating app seeks strategic options amid ongoing challenges in user growth and monetization + Recent price target 🎯 of $6.10 from Citi + Recent price target 🎯 of $5.26 from GF Value + Recent price target 🎯 of $4 from consensus

Gain access to all our cutting-edge research tools, live watchlists, alerts, and more: https://www.squeeze-finder.com/subscribe

HINT: Use code RDDT to get your first month for just $10!

NOT FINANCIAL ADVICE, THESE POSTS ARE FOR INFORMATIONAL PURPOSES ONLY

Here’s one I just came across today. Apparently big shorts knocked this down this morning and it seems like any kind of buying pressure makes this jump up pretty quickly. I have a 600 share position. 4-5 is the target 🎯

​

Extreme low floater that's been spiking multiple times in premarket past weeks. Shorts come back and reload, all the time.

Treat this one as purely speculative🚀🚀, not financial advice.

Most recent (daily) cost to borrow and shares available:

https://chartexchange.com/symbol/nasdaq-frgt/borrow-fee/

Shares outstanding and cash position:

https://dilutiontracker.com/app/search/FRGT

FRGT on reg sho threshold list = if a ticker is on it, alot of fails to deliver and eventually prone to shorts forced closing of their positions:

https://www.nasdaqtrader.com/trader.aspx?id=regshothreshold

People hoping for a squeeze in $HTZ it'll never happen as they are actively diluting into any spikes.

The only squeeze can be the 10x chicken feet stonk.

Super low free float. Shares locked up (unlike the car hire stonk). And high CTB. This can move fast and quick especially when it's pumped on WeChat.

🐥🐔🦶

🔥 HTZ SHORT SQUEEZE SETUP 🔥

HTZ is sitting on a massive short position with 8+ days to cover. If the stock clears $2.00–$2.10 with heavy volume, things could get explosive. 🚀

🎯 Trade: Jan. Calls $2
📈 Targets: $4
🛑 Invalidation: ~$1.50–$1.55

The setup: breakout → short covering → momentum → potential squeeze.
HTZ could get interesting FAST. 🚀🔥

I’ve been watching Xponential Fitness (XPOF) pretty closely over the last several sessions, including price action, Level 2, time & sales, FINRA/off-exchange prints, volume, short interest, moving averages, MACD, RSI, and options positioning.
I’m not posting this as a “MOASS tomorrow” prediction. There are some legitimate bullish ingredients here, but there are also several things XPOF still has to prove.
Here’s what I’m seeing.
The short-interest setup is legitimate
The most recent data we reviewed showed roughly:
10.31 million shares short
Approximately 27.5%+ of the float short
Roughly 11–15 days to cover, depending on the volume period being used
That is objectively elevated short interest.
But I think people need to make an important distinction:
High short interest doesn’t equal trapped shorts.
At ~$4.70–$4.90, I don’t think you can confidently say the shorts are trapped yet. My line in the sand is higher. If XPOF starts establishing itself above roughly $5.20 and especially $5.50, then the pressure on newer short positions becomes considerably more interesting.
Until then, this is short-squeeze potential, not a confirmed squeeze.

The daily chart has quietly improved a lot
The stock recently bottomed around $3.565 and has now recovered into the upper $4s.
As of today, XPOF was around $4.76–$4.80, after reaching an intraday high of approximately $4.91.
The daily chart currently shows:
20-day MA: ~$4.10
50-day MA: ~$4.94
200-day MA: ~$6.37
RSI(14): ~57
MACD still below zero, but improving substantially
Positive/rising MACD histogram
That matters.
The stock has moved from roughly $3.56 to the $4.70s while:
creating higher lows,
recovering above the 20-day MA,
improving RSI,
improving MACD,
and now testing the declining 50-day moving average.
That’s a much healthier chart than it was several weeks ago.
The long-term trend is not bullish yet because XPOF remains well below the 200-day MA. But the intermediate reversal attempt is real.

$4.90–$5.00 is the battlefield
This is probably the most important part of the setup right now.
Today’s intraday high was approximately $4.91.
The 50-day moving average is around $4.94.
Then you have the obvious psychological level at $5.00.
So essentially you’ve got:
$4.91 → $4.94 → $5.00
all stacked together.
That’s a significant resistance zone.
Earlier analysis also identified additional resistance around:
$5.19–$5.23
and then roughly:
$5.39–$5.50
A move through $5 isn’t enough by itself for me. What would get my attention is:
break $5 → hold/retest it → clear $5.20 → continue on increasing volume.
That would be a very different technical setup.

There has been a lot of off-exchange/FINRA activity
I’ve also been watching the tape.
Today, for example, XPOF was trading around $4.81 with an NBBO around:
$4.81 bid / $4.82 ask
At one point the visible inside market was approximately:
600 shares bid vs. 300 offered
and a FINRA print occurred around $4.825, slightly above the displayed ask.
That’s constructive.
Later, around the $4.77 area, the bid repeatedly appeared/replenished while multiple trades printed around $4.775, including activity reported through FINRA and several lit venues.
This is where people need to be careful with “dark pool” terminology.
A FINRA print does not automatically mean institutional accumulation.
FINRA generally tells you the trade occurred off exchange. It doesn’t magically tell you:
“BlackRock just bought this.”
What I’m interested in is the behavior around those executions.
If sellers repeatedly hit a price and:
shares execute → bid replenishes → price refuses to break lower
that’s evidence consistent with absorption.
If a large bid simply appears and disappears without executions, that’s much less meaningful.
Right now I see possible absorption, but I would not claim it has been conclusively proven.

Today’s intraday action actually gave us a useful test
Earlier today XPOF ran to approximately $4.91, then pulled back toward:
$4.81 → $4.78 → $4.76
The 5-minute chart weakened:
Price moved below VWAP
MACD turned negative intraday
RSI dropped into the mid-30s
Lower highs/lower lows appeared
At first glance that looks bad.
But zoom out to the daily chart and the picture changes.
The stock basically ran straight into its 50-day moving average around $4.94 and got rejected.
That’s a technically logical place for profit-taking and short pressure to appear.
The question now isn’t whether XPOF can trade $4.76 instead of $4.80 for a few minutes.
The bigger question is whether the stock can hold the broader breakout structure and attack $4.94–$5.00 again.

The options setup adds another interesting wrinkle
One thing that stood out in the options data was significant positioning around the $5 strike, including negative gamma exposure.
That’s relevant because $5 isn’t just psychologically important.
It’s also an area where dealer hedging dynamics could potentially increase volatility if the stock begins moving decisively through the strike.
Again, that doesn’t guarantee upside.
Negative gamma can amplify moves in either direction.
But combined with the short interest and technical resistance sitting in essentially the same area, $5 is clearly the level I’m watching.

My key levels
This is how I’m currently viewing the chart:

Price
Why it matters
$6.35–$6.40
200-day MA / major longer-term resistance
$5.50
Area where the “trapped shorts” argument becomes much stronger
$5.39–$5.40
Secondary resistance
$5.19–$5.23
Important breakout resistance
$4.94–$5.00
50DMA + psychological resistance + options battle
$4.85–$4.91
Immediate resistance
$4.75–$4.80
Current battle/support area
$4.60–$4.66
Important short-term support
~$4.10
20-day MA
$3.565
Recent swing low

What would make me bullish
The sequence I want to see is something like:
$4.70s hold
→ $4.85 reclaimed
→ $4.91 breaks
→ $4.94–$5.00 breaks on real volume
→ $5 retest holds
→ $5.20 breaks
At that point I think the setup becomes significantly more interesting because technical traders, momentum traders, options hedging, and short covering could all start interacting.
The most important thing would be volume confirmation.
A $5.05 print on thin volume means much less to me than sustained trading above $5 with volume expanding.

What would invalidate the thesis
I’m not ignoring the downside.
If XPOF:
continuously fails at $4.90–$5,
loses the mid-$4.60s,
falls back below the 20-day MA,
and off-exchange activity keeps occurring while price continues making lower lows,
then what looks like accumulation today could turn out to have been distribution.
That’s why I don’t think the “dark pools are loading before the squeeze” narrative should be treated as established fact.
Price ultimately has to confirm it.

Bottom line
To me, XPOF currently has an unusual combination of:
~27%+ short interest
double-digit days to cover
major recovery from $3.565
improving daily MACD
RSI back above 50
price above the 20DMA
heavy off-exchange activity
repeated defense around the upper $4s
50DMA sitting almost exactly at $5
significant options positioning around $5
That’s enough to keep it on my radar.
But I don’t think the evidence justifies saying:
“The squeeze has started.”
Not yet.
For me, $4.94–$5.00 is the door. $5.20 is confirmation. $5.50 is where the short thesis potentially starts getting uncomfortable.
Until price proves it, this remains a high-short-interest reversal setup with potential, not a guaranteed squeeze.

Not financial advice. Do your own DD. I’m posting this mainly because there seems to be considerably more going on underneath XPOF than the headline price movement suggests.

chicken feet guy back 🐔🦶🦶

first, a public service announcement: I love sucking on fried chicken feet. fried, then braised in black bean sauce at dim sum, sticky, garlicky, pure collagen. you gnaw the little knuckles, spit the bones, order another basket. if you've never had them you haven't lived.

WYHG makes cured meats. I'm choosing to believe feet are involved.

I posted it here at $3.50 in July. Aug 6 it hit $23 with multiple halts. the feet have run before 🦶

why I'm hungry again:

🔥 borrow fee ~607%. bouncing between 550% and 709% for two weeks. at the $23 top it was 355%. shorts are paying ~1.7% a day to stay in.

🪫 the lendable pool keeps draining. 25k → 20k → 15k → 10k today. yesterday it hit 85 shares.

🔒 tiny float, locked supply. the September placement (23m shares at ~$1.12) is locked for a year. tradeable float is still ~600k.

the play: borrow is already as tight as it's ever been. if volume comes back and shorts pile in at 600%+ CTB with a pool this thin, July is back on the menu. watching DTC, short volume and FTDs.

Good morning, SqueezeFinders!

Yesterday’s price action on the $QQQ tech index was indicative of ongoing bullish euphoria despite all the ongoing issues in the world ranging from the emergence of the pneumococcal plague, ongoing developments in the Middle-East, the war in Russia/Ukraine, and also ongoing panic in the bond market. The $QQQ tech index made yet another new all-time high yesterday of 756.92 and closed at 756.20 (+0.88%). The main support level to watch is ~736, and otherwise we remain in an extremely bullish position for the market. The main directional sentiment determinants today are the aforementioned factors. This market is very dynamic and has been unpredictable as far as risk-tolerance goes, as one day we're running, and the next we're crashing. Stay tuned for what's squeezy. Regardless of broader market sentiment, you can always locate relative strength by checking SqueezeRadar to track irregularities in our data, and find winners you may not have spotted before without our scanners. Also, make sure to check out our newest tool (developed by me), "Dracula's Library"! This tool allows you to quickly gather information on recent catalysts, and analyst/Institutional price targets all in one small graphical interface on our platform, all powered by AI.

🥇 Gold: ~$4,160/oz (+0.1%)
🥈 Silver: ~$61/oz (-0.3%)
🪙 Bitcoin: ~$85.7k/coin (-1.1%)
🛢️ Oil: ~$89.50/barrel (0.0%)

Today's economic data releases are:

🇺🇸 ADP Employment Change Weekly @ 8:15AM ET
🇺🇸 Trade Balance (Aug) @ 8:30AM ET
🇺🇸 Exports (Aug) @ 8:30AM ET
🇺🇸 Imports (Aug) @ 8:30AM ET
🇺🇸 FOMC Member Bowman Speaks @ 10:45AM ET
🇺🇸 Atlanta Fed GDPNow (Q3) @ 11:30AM ET
🇺🇸 EIA Short-Term Energy Outlook @ 12:00PM ET
🇺🇸 3-Year Note Auction @ 1:00PM ET
🇺🇸 API Weekly Crude Oil Stock @ 4:30PM ET
🇺🇸 FOMC Member Williams Speaks @ 9:05PM ET

📙Breakdown point: BELOW this price, the move will lose momentum significantly in the short-term, as shorts will gain confidence encouraging them to short more. Reducing probability of a squeeze without a catalyst.

📙Breakout point: ABOVE this price, the move will gain momentum significantly in the short-term, as shorts losses will increase pressuring them to cover. Increasing the probability of a squeeze occurring, especially if with a catalyst.

1. $OSPN
   Squeezability Score: 42%
   Juice Target: 28.3
   Confidence: 🍊 🍊 🍊
   Price: 18.42 (+1.66%)
   Breakdown point: 15.8
   Breakout point: 19.3
   Mentions (30D): 4
   Event/Condition: OneSpan is acquiring Build38 to deepen mobile application security as part of a broader cyber-security consolidation wave, with the deal cited alongside other sector M&A as a growth lever for authentication and app protection + Bank of America opened a new position while institutions already hold the large majority of the float and the shares trade near a 52-week high after Q2 subscription growth and a raised full-year outlook of $248–$252 million in revenue and $67–$71 million in adjusted EBITDA + DigipassONE and the FIDO2 and digital-agreements mix remain the core proof points analysts are using to underwrite margin and ARR upside + Recent price target 🎯 of $18 from Needham + Recent price target 🎯 of $18 from consensus analysts + Recent price target 🎯 of $17 from Rosenblatt

2. $ERO
   Squeezability Score: 37%
   Juice Target: 50.5
   Confidence: 🍊 🍊 🍊
   Price: 38.44 (+1.4%)
   Breakdown point: 35.0
   Breakout point: 40.9
   Mentions (30D): 4
   Event/Condition: CIBC raised its target to C$56 from C$52 and kept a Neutral rating after touring the three operating assets, while Wall Street Zen upgraded the shares to Buy as the stock held near a 52-week high + the company set November 2 for third-quarter operating and financial results after a prior quarter that beat on both earnings and revenue, with copper production and the Tucumã ramp still the main operating drivers + Bank of America remains at Buy after its earlier upgrade, and the Street’s average target sits modestly above the recent close on Brazil copper and gold exposure + Recent price target 🎯 of $44 from consensus high + Recent price target 🎯 of $40.73 from consensus analysts + Recent price target 🎯 of $34 from Bank of America

Gain access to all our cutting-edge research tools, live watchlists, alerts, and more: https://www.squeeze-finder.com/subscribe

HINT: Use code RDDT to get your first month for just $10!

NOT FINANCIAL ADVICE, THESE POSTS ARE FOR INFORMATIONAL PURPOSES ONLY

NVAX offers an attractive short-squeeze setup, with roughly 55**% of its float sold short** and about 9 days to cover. Strong upward momentum and elevated volume could force additional short covering.

Sanofi COVID/flu combination vaccine — potentially the biggest near-term catalyst.
Sanofi is in advanced discussions with regulators on the timing of a Phase 3 COVID/flu combination trial. Starting that Phase 3 trial would trigger a $125 million milestone payment to Novavax. There is another potential $225 million launch milestone later.

Risk: Exit if the breakout fails and momentum reverses.

Preferred strategy: Use call options to limit downside risk and multiply your long trade with massive leverage.

The stock is currently trading at over 40 million volume, around 9x its average, and up around 50%. VEEA has some crazy analytics and if you would like to see some more info on it go to my most recent article talking about its stats and catalyst.

1 - Heavily Shorted:

SI: 30%

2 - Low Float:

5 M shares floating out of 50M

3 - $SKY Coin Treasury:

Owns 10%, earning approx. 6% APR

4- Gap to fill:

a) $15.47
b) $58.75

5) Read below and google AI the float:

Deal Overview & Mechanics:

• Rebrand: NovaBay shifted from eye care to a crypto holding company, trading as SDEV on the NYSE American.

• Funding: Raised $134 million via a private placement involving cash and stablecoins from investors like Tether Investments and Framework Ventures.

• Holdings: Holds ~2.15 billion SKY tokens (~9.15% of total supply).

• Staking Strategy: Substantially all acquired tokens are actively staked in the Sky Protocol to generate yield.

Sometimes, love don't feel like it should... HTZ so good

Oct 2 PR: NASDAQ Hearings Panel says they stay listed on NASDAQ -- resulting from the 1:8 reverse split that took effect on Aug 28 (post-split price approx $4.08).

• NASDAQ Hearings Panel Decision
• So far, the share price hit $4.95 today!
• Shareholders who lacked confidence sold and short sellers together pushed the price down to $2.65 yesterday -- likely because the Hearings Panel had not responded within their normal time frame and their decision came late.
• This PR confirms what my post from two months ago stated, which is the CEO confirms their proforma annual revenue run rate is $30M.
• The $54M, cybersecurity 10-year deal they announced on July 30 begins installation in November.
• The $30M does not include annual revenue that will result as of all deals closed in the 4th quarter of 2026, of which there was a pipeline of $11M late-stage sales cycle opportunities as of about a month ago.

Sep 29 PR: Resolved John Doe defamation lawsuit that Cycurion filed.

• John Doe Defamation Lawsuit Resolved
• Cycurion had firm evidence of coordinated stock manipulation of CYCU on two occasions, including short selling spiking, spoofing, short sale circuit breaker triggering.
• Though they won this pivotal lawsuit, they are not done yet and are going after monetary damages. Here's the statement from the above lawsuit link that tells us it is likely the goal:
  • "Full and truthful cooperation. The defendant has agreed to cooperate regarding short selling and naked short selling of Cycurion stock, and any coordination with other investors, short sellers, or market makers relating to Cycurion securities."

Shares Available to Borrow Today:

• 1,000 shares available to borrow at Interactive Brokers
  • 15,000 shares available at 8:54 AM
  • 10,000 shares at 9:09 AM
  • 500 shares at 9:56 AM
  • 1,000 shares at 10:44 AM
  • Availability collapsed from 15K → 1K intraday

Cost to Borrow Today

• 72.1% – 75.9% annualized (today’s intraday range) iborrowdesk.comiborrowdesk.com.

I maintain and agree with the CEO that CYCU is very undervalued right now!

It should be nothing but good news from here on, and any notable increase in short selling along with good-news PRs about contract wins should cause the share price to jump in a meaningful way.

HTZ up 1.5% earlier and now headed back up. Some resistance at $1.70 but she wants to break through.

VEEA just announced a commercial agreement with TROLLEE to deploy VeeaONE across up to 1,000 unattended stores, starting with up to 50 locations. Veea estimates $1,000–$2,000 per store, putting the potential full rollout at approximately $1M–$2M. This is a major commercial deployment relative to VEEA’s current size, with TROLLEE planning to scale across its unattended store network.

The squeeze setup is insane: 1.22M shares short, 80.01% short float, 45.01 days to cover, and a 788.30% borrow rate, with only 1.59M shares in the public float. VEEA traded 68.8M shares, around 16x its average volume of 4.28M. The stock jumped around 54% so far, expecting more in the after market.

https://www.globenewswire.com/news-release/2026/10/01/3372844/0/en/veea-announces-trollee-agreement-for-phased-deployment-of-veeaone-to-1-000-unattended-stores.html

NFA. DD.

Last year the short squeeze never took off, but I did swing trade it between the 3 to 5 range. Currently trading at historic lows. Losses shrinking. 1.5 billion revenue a year, Market cap is around 150 million.

No guarantee it will trigger this time, but sharing it just so if it happens you won't be able to say "why didn't anyone tell me about it" so I just did

It's a seasonal stock and the earnings in October 29th is expected to be weak. But it's so beat-down that anything better than terrible will be great for it

I won’t bore you with statistics or fundamentals. I’m a momentum trader — I read the tape, price action and pattern recognition.

Great PR today, on top of another good PR 5 days ago.

It ran to 0.2145 then pulled back and reversed at 0.181. Then they pushed it up to 0.2185. After that it pulled back and spent most of later AH chopping around 0.195–0.205.

In my eyes they have been repeatedly retrapping bears around these levels. The key point for me is 0.18. That’s where the major reversal happened, and so far it’s holding.

Now we’re seeing heavy selling overnight, but 0.18 is still holding for now. I actually like seeing the volume and the fight at that levels, it gives more information about how the tape reacts.

I’m in at 0.181, and I think we could see strong continuation tomorrow if 0.18 continues to hold and the selling fails to produce a sustained breakdown.

This is my personal thesis, not investment advice. Do your own DD.

I don’t have much to cover on this trash but for the LIFE OF ME I can not find a post covering this damn thing. So, I found this stock on RH price jumps radar and the numbers are obnoxious. 100% + Short float and uhh 1,120% Borrow rate.. Bruh😑 Can some fellow degens tell me am I trippin orrrrr are these some numbers we haven’t seen numbers like this since 2021….

**Edit** 1000 views in two minutes and not one comment, let me get an answer from somebody im not PROMOTING GYGY

Good morning, SqueezeFinders!

Yesterday's price action on the $QQQ tech index showed the bears are still putting up a fight even near all-time highs. The close at 736.53 (-1.07%) preventing a new all-time high by ~1.5%. The main support to hold is at ~724 before we ought to worry about any potential directional sentiment switch. The main directional sentiment determinants for today are a mix of the below-detailed economic data releases, further developments overseas with both ongoing wars, and ongoing efforts to calm the bond market. This market is very dynamic and has been unpredictable as far as risk-tolerance goes, as one day we're running, and the next we're crashing. Stay tuned for what's squeezy. Regardless of broader market sentiment, you can always locate relative strength by checking SqueezeRadar to track irregularities in our data, and find winners you may not have spotted before without our scanners. Also, make sure to check out our newest tool (developed by me), "Dracula's Library"! This tool allows you to quickly gather information on recent catalysts, and analyst/Institutional price targets all in one small graphical interface on our platform, all powered by AI.

🥇 Gold: ~$4,160/oz (-0.2%)
🥈 Silver: ~$61/oz (-1.5%)
🪙 Bitcoin: ~$83.1k/coin (-0.5%)
🛢️ Oil: ~$94.20/barrel (+1.8%)

Today's economic data releases are:

🇺🇸 CB Consumer Confidence (Sep) @ 10:00AM ET
🇺🇸 JOLTS Job Openings (Aug) @ 10:00AM ET
🇺🇸 FOMC Member Bowman Speaks @ 11:00AM ET
🇺🇸 Fed Vice Chair for Supervision Barr Speaks @ 12:40PM ET
🇺🇸 FOMC Member Williams Speaks @ 2:00PM ET
🇺🇸 Fed Waller Speaks @ 3:00PM ET
🇺🇸 API Weekly Crude Oil Stock @ 4:30PM ET

📙Breakdown point: BELOW this price, the move will lose momentum significantly in the short-term, as shorts will gain confidence encouraging them to short more. Reducing probability of a squeeze without a catalyst.

📙Breakout point: ABOVE this price, the move will gain momentum significantly in the short-term, as shorts losses will increase pressuring them to cover. Increasing the probability of a squeeze occurring, especially if with a catalyst.

1. $MX
   Squeezability Score: 37%
   Juice Target: 5.3
   Confidence: 🍊
   Price: 3.79 (+14.85%)
   Breakdown point: 3.5
   Breakout point: 5.1
   Mentions (30D): 1
   Event/Condition: Navitas Semiconductor agreed to a $5 million strategic equity investment at $3.42 per share deepening the July silicon-carbide partnership that licenses GeneSiC Gen 4 and Gen 5 technology for high-voltage and ultra-high-voltage power markets + CEO Chae Lee bought 100,000 shares in open-market purchases over two days signaling insider confidence as the company pivots toward a pure-play power-semiconductor mix including 6th-generation 600V SJ MOSFETs for AI servers and EV charging + Q2 gross margin beat guidance even as legacy product pricing remained pressured with a 2026 plan to ship 55 new-generation products and lift new-product revenue mix into the fourth quarter + Recent price target 🎯 of $5 from Needham + Recent price target 🎯 of $4.50 from B. Riley + Recent price target 🎯 of $6 from Roth Capital

2. $VCX
   Squeezability Score: 23%
   Juice Target: 55.4
   Confidence: 🍊
   Price: 28.17 (-6.66%)
   Breakdown point: 18.0
   Breakout point: 47.0
   Mentions (30D): 0 🆕
   Event/Condition: Closed-end Fundrise Innovation Fund remains a public proxy for private growth-tech holdings including Databricks and AI-related vehicles while trading at a wide premium to last published NAV which continues to drive volatility and halt-resume activity + September prospectus update set pricing limits as the fund sold additional shares while still trading well above reported asset value + lockup on restricted shares was moved forward by a month earlier in the year leaving secondary supply and private-market marks as the main near-term swing factors for the listed vehicle + Recent price target 🎯 of $35 from Needham + Recent price target 🎯 of $32 from B. Riley + Recent price target 🎯 of $40 from Roth Capital

Gain access to all our cutting-edge research tools, live watchlists, alerts, and more: https://www.squeeze-finder.com/subscribe

HINT: Use code RDDT to get your first month for just $10!

NOT FINANCIAL ADVICE, THESE POSTS ARE FOR INFORMATIONAL PURPOSES ONLY